ByteDance spins out AI drug startup AnewLabs with $290M raise at $1.5B valuation

创业邦 · wechat · 2026-09-18

ByteDance has spun out its five-year-old AI drug discovery team as AnewLabs, which closed a $290M first external round at a $1.5B post-money valuation, led by HSG (Sequoia China), IDG Capital, and Hillhouse, with ByteDance retaining 56% control. The core team of 50 was formed in 2021 by Liu Kai.

Key points:

Related event: ByteDance Spins Off AI Drug Discovery Unit Anew Labs with $290M Raise(3 posts)→

Original post →

More from Venture

Venture channel →